Released Mar 6, 2017, after the close
10-K filed Mar 9, 2017, 68 days after period end · 0001493152-17-002280
Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.98M$5.98M derived−8.3% vs Q4 2015+9.9% vs Q3 2016
Net Income-$459.00K-$459.00K derivedN/M vs Q4 2015N/M vs Q3 2016
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$300,000N/M
Operating Cash Flowderived$51,000N/M
Free Cash Flowderived-$70,000N/M
Margins · derived
Operating margin-5.0%+8.8 pt vs Q4 2015
Net margin-7.7%+7.5 pt vs Q4 2015
What the release said
The release
Same quarter
| Metric | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.98M | $6.52M | $6.75M | $6.58M |
| Net Income | -$459.00K | -$990.00K | -$1.72M | -$351.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR